Dabrafenib –trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non–small-cell lung cancer

We read with great interest the article by Facchinetti et  al. [1] about the molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E-mutant non–small-cell lung cancer (NSCLC). The article indicates that understanding the mechanisms of acquired resistance to BRAF and MEK inhibitors in NSCLC is important to discover novel treatment stra tegies. Currently, it is difficult for clinicians to perform molecular re-analysis in the real world. Here, we report the case of achieving a long-term partial response (PR) to dabrafenib-trametinib combination therapy (D/T) re-challenge in advanced BRAFV600E-mutant NSCLC.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research